We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
Organon (OGN - Free Report) closed the most recent trading day at $6.23, moving -2.5% from the previous trading session. This move lagged the S&P 500's daily loss of 1.36%. Meanwhile, the Dow experienced a drop of 1.64%, and the technology-dominated Nasdaq saw a decrease of 1.46%.
Heading into today, shares of the pharmaceutical company had lost 12.23% over the past month, lagging the Medical sector's loss of 5.66% and the S&P 500's loss of 1.76%.
The investment community will be paying close attention to the earnings performance of Organon in its upcoming release. It is anticipated that the company will report an EPS of $0.84, marking a 17.65% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $1.46 billion, indicating a 3.27% decrease compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.37 per share and a revenue of $6.16 billion, signifying shifts of -7.92% and -0.86%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Organon. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.72% lower. Organon is currently a Zacks Rank #5 (Strong Sell).
Looking at valuation, Organon is presently trading at a Forward P/E ratio of 1.89. This denotes a discount relative to the industry average Forward P/E of 15.34.
Meanwhile, OGN's PEG ratio is currently 0.57. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.43.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 86, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
Organon (OGN - Free Report) closed the most recent trading day at $6.23, moving -2.5% from the previous trading session. This move lagged the S&P 500's daily loss of 1.36%. Meanwhile, the Dow experienced a drop of 1.64%, and the technology-dominated Nasdaq saw a decrease of 1.46%.
Heading into today, shares of the pharmaceutical company had lost 12.23% over the past month, lagging the Medical sector's loss of 5.66% and the S&P 500's loss of 1.76%.
The investment community will be paying close attention to the earnings performance of Organon in its upcoming release. It is anticipated that the company will report an EPS of $0.84, marking a 17.65% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $1.46 billion, indicating a 3.27% decrease compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.37 per share and a revenue of $6.16 billion, signifying shifts of -7.92% and -0.86%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Organon. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.72% lower. Organon is currently a Zacks Rank #5 (Strong Sell).
Looking at valuation, Organon is presently trading at a Forward P/E ratio of 1.89. This denotes a discount relative to the industry average Forward P/E of 15.34.
Meanwhile, OGN's PEG ratio is currently 0.57. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.43.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 86, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.